These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39144145)

  • 1. Successful treatment of relapsed and refractory CIDP with ofatumumab: a first case report.
    Wang J; Xiang Q
    Front Immunol; 2024; 15():1437848. PubMed ID: 39144145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies.
    Casertano S; Signoriello E; Rossi F; Di Pietro A; Tuccillo F; Bonavita S; Lus G
    Eur J Neurol; 2020 Dec; 27(12):2673-2675. PubMed ID: 32875645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.
    Melzer N; Meuth SG
    Clin Exp Immunol; 2014 Mar; 175(3):359-72. PubMed ID: 24032475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy.
    Cao S; Du J; Pan S; Zhang J; Xu S; Wei L; Tian Y
    Front Immunol; 2023; 14():1164181. PubMed ID: 37223100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after secukinumab: case report.
    Jin Y; Chu H; Dong H; Wang H; Wang Q; Zhao X; Qin D; Lu Z; Weng C
    BMC Neurol; 2022 Nov; 22(1):400. PubMed ID: 36324078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
    Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
    Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
    Tracy JA; Dyck PJ
    Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic inflammatory demyelinating polyneuropathy with pulmonary nocardiosis: A case report.
    Yan C; Liu TT; Gao LT
    Medicine (Baltimore); 2024 Jun; 103(24):e38544. PubMed ID: 38875438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
    Lopate G; Pestronk A; Al-Lozi M
    Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two Case Reports of Chronic Inflammatory Demyelinating Polyneuropathy After COVID-19 Vaccination.
    Kim S; Lee EK; Sohn E
    J Korean Med Sci; 2023 Feb; 38(8):e57. PubMed ID: 36852853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression.
    Hung SKY; Hiew FL; Viswanathan S; Puvanarajah S
    J Peripher Nerv Syst; 2018 Sep; 23(3):183-189. PubMed ID: 30027593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
    Chan YC; Allen DC; Fialho D; Mills KR; Hughes RA
    J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):114-6. PubMed ID: 16361609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.
    Hu J; Sun C; Lu J; Zhao C; Lin J
    J Neurol; 2022 Mar; 269(3):1250-1263. PubMed ID: 34120208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids.
    Muley SA; Kelkar P; Parry GJ
    Arch Neurol; 2008 Nov; 65(11):1460-4. PubMed ID: 19001164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.